Regeneron Pharmaceuticals, Inc.REGN
Price$734.81Intrinsic value$882.0220% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $882.02median of 6 methods · middle span $714-$2,896based on filings through 30 Jun 2026
Market Price $734.81Price as of 1 Oct 2026
Margin of Safety +20.0%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 1.0% (near-term consensus, capped) · years 2–5: 19.3%/yr (balance of the path).15.4% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 617.4%Yr 715.6%Yr 813.7%Yr 911.9%Yr 1010.0%
19.3% → 10.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 119.3%Yr 128.6%Yr 137.9%Yr 147.2%Yr 156.5%Yr 165.8%Yr 175.1%Yr 184.4%Yr 193.7%Yr 203.0%
10.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)10.0%
Discount rate (cost of equity) 7.0%
Volatility vs market (adjusted beta)0.46

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetRegeneron Pharmaceuticals, Inc.REGNHealth Care
Valuation
P/E18.2×
P/S5.2×
P/B2.6×
EV / Revenue5.2×
EV / EBITDA—
Profitability
Gross margin81.9%
Operating margin24.9%
Net margin27.9%
FCF margin24.2%
Returns
ROE13.7%
ROA10.4%
ROIC13.9%
Growth
Revenue growth (YoY)9.4%
5-yr fwd EPS growth15.4%
Financial strength
Debt / Equity0.06×
Current ratio3.34×
Altman Z-Score7.3
Interest coverage—
Dividend yield0.2%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.